The drug is being developed to treat a heart condition called hypertrophic cardiomyopathies, which causes the thickening of heart muscles and can lead to cardiac arrest. Late-stage data from the drug is expected later this year.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/SUueGRy
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Cytokinetics to focus on heart disease drug after ALS trial failure
https://ift.tt/KrHot5z
No comments:
Post a Comment